Trials / Terminated
TerminatedNCT04267393
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (NASH)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 21 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986263 | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2021-03-17
- Primary completion
- 2023-08-16
- Completion
- 2024-02-09
- First posted
- 2020-02-12
- Last updated
- 2024-09-04
- Results posted
- 2024-09-04
Locations
112 sites across 16 countries: United States, Argentina, Belgium, Brazil, Canada, France, Germany, Israel, Italy, Japan, Puerto Rico, South Korea, Spain, Switzerland, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04267393. Inclusion in this directory is not an endorsement.